Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Mocroft

Showing results (31-40 of 116) with videos related to

Pageof 12
Sort By:
AIDS (London, England)|July 15, 1997
Survival after a very low (< 5 x 10(6)/l) CD4+ T-cell count in individuals infected with HIVC A Sabin, A Mocroft, M Bofill, et al.
BMJ (Clinical Research Ed.)|February 8, 1997
Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. Royal Free/Chelsea and Westminster Hospitals Collaborative GroupA Mocroft, M Youle, J Morcinek, et al.
HIV Medicine|December 12, 2001
Assessing the cost-effectiveness of HAART for adults with HIV in EnglandA H Miners, C A Sabin, P Trueman, et al.
AIDS (London, England)|August 26, 1998
Evaluating the effect of year of seroconversion on HIV progression in cohort studies. Italian Seroconversion StudyA Cozzi Lepri, A N Phillips, P Pezzotti, et al.
AIDS (London, England)|July 24, 1998
A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responsesA Cozzi Lepri, G D Smith, A Mocroft, et al.
Antiviral Therapy|September 6, 2000
Virological failure among patients on HAART from across Europe: results from the EuroSIDA studyA Mocroft, V Miller, A Chiesi, et al.
The Journal of Infectious Diseases|November 7, 1998
Changes in lymphocyte subsets in human immunodeficiency virus-positive persons with < 5 CD4 T lymphocytes/mm3C A Sabin, A Mocroft, M Bofill, et al.
HIV Medicine|October 30, 2009
Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavirJ D Kowalska, O Kirk, A Mocroft, et al.
Clinical Trials (London, England)|June 16, 2006
The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) eraA Mocroft, J Neaton, J Bebchuk, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 3, 2004
Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001I Yust, Z Fox, M Burke, et al.
Pageof 12

Showing results (31-40 of 116) with videos related to

Sort By:
Pageof 12
AIDS (London, England)|July 15, 1997
Survival after a very low (< 5 x 10(6)/l) CD4+ T-cell count in individuals infected with HIVC A Sabin, A Mocroft, M Bofill, et al.
BMJ (Clinical Research Ed.)|February 8, 1997
Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. Royal Free/Chelsea and Westminster Hospitals Collaborative GroupA Mocroft, M Youle, J Morcinek, et al.
HIV Medicine|December 12, 2001
Assessing the cost-effectiveness of HAART for adults with HIV in EnglandA H Miners, C A Sabin, P Trueman, et al.
AIDS (London, England)|August 26, 1998
Evaluating the effect of year of seroconversion on HIV progression in cohort studies. Italian Seroconversion StudyA Cozzi Lepri, A N Phillips, P Pezzotti, et al.
AIDS (London, England)|July 24, 1998
A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responsesA Cozzi Lepri, G D Smith, A Mocroft, et al.
Antiviral Therapy|September 6, 2000
Virological failure among patients on HAART from across Europe: results from the EuroSIDA studyA Mocroft, V Miller, A Chiesi, et al.
The Journal of Infectious Diseases|November 7, 1998
Changes in lymphocyte subsets in human immunodeficiency virus-positive persons with < 5 CD4 T lymphocytes/mm3C A Sabin, A Mocroft, M Bofill, et al.
HIV Medicine|October 30, 2009
Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavirJ D Kowalska, O Kirk, A Mocroft, et al.
Clinical Trials (London, England)|June 16, 2006
The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) eraA Mocroft, J Neaton, J Bebchuk, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 3, 2004
Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: a EuroSIDA study, 1994-2001I Yust, Z Fox, M Burke, et al.
Pageof 12